Compare MSGM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | LGVN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 34.0M |
| IPO Year | 2020 | 2021 |
| Metric | MSGM | LGVN |
|---|---|---|
| Price | $4.04 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 46.4K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | 50.76 |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $741,000.00 | $709,000.00 |
| Revenue This Year | $69.73 | N/A |
| Revenue Next Year | $146.81 | $10.81 |
| P/E Ratio | $2.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $0.48 |
| 52 Week High | $5.78 | $1.83 |
| Indicator | MSGM | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 59.82 |
| Support Level | $3.65 | $0.69 |
| Resistance Level | $4.57 | $1.23 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 56.41 | 66.10 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.